Shares of Astrazeneca PLC (NYSE:AZN) have earned an average rating of “Buy” from the twenty-five analysts that are currently covering the stock. Three analysts have rated the stock with a sell recommendation, eight have given a hold recommendation, eleven have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $38.69.

Several analysts have issued reports on the company. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. set a $41.40 target price on Astrazeneca PLC and gave the company a “buy” rating in a report on Thursday, September 8th. Piper Jaffray Cos. assumed coverage on Astrazeneca PLC in a report on Friday, September 23rd. They issued an “overweight” rating for the company. Deutsche Bank AG restated a “buy” rating on shares of Astrazeneca PLC in a report on Monday. Finally, TheStreet upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Friday, July 22nd.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 30.80 on Monday. The company has a market capitalization of $77.92 billion, a P/E ratio of 35.20 and a beta of 0.75. The company has a 50 day moving average price of $33.02 and a 200 day moving average price of $30.86. Astrazeneca PLC has a 12-month low of $26.97 and a 12-month high of $35.04.

Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.76 by $0.07. The company earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm’s quarterly revenue was down 4.0% on a year-over-year basis. During the same period in the prior year, the business earned $1.21 EPS. Equities analysts anticipate that Astrazeneca PLC will post $2.97 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Forester Capital Management LTD increased its position in Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. First Interstate Bank increased its position in Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares in the last quarter. Synovus Financial Corp increased its position in Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Fifth Third Bancorp increased its position in Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Finally, Integrated Investment Consultants LLC increased its position in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Hedge funds and other institutional investors own 11.39% of the company’s stock.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.

5 Day Chart for NYSE:AZN

Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.